Using computer modeling and algorithms to help develop new drugs for central nervous system diseases is rare. But the quietly growing French biotech Rhenovia Pharma SAS is building on pioneering work conducted at the University of Southern California with the aim of leading the field.
Rhenovia was set up in 2007 and raised €350,000 ($460,000) in 2009 in a first seed financing round
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?